2015 Fiscal Year Final Research Report
Development of MIF vaccine therapy against inflammation-related colon carcinogenesis
| Project/Area Number |
24501332
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor immunology
|
|---|
| Research Institution | Hokkai-Gakuen University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATO Takuma 三重大学, 大学院医学系研究科, 准教授 (60224515)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Keywords | ワクチン療法 / 抗自己サイトカイン / IBD / MIF / 発がん |
|---|
| Outline of Final Research Achievements |
MIF DNA vaccine shows a preventive and therapeutic effect in a number of models of inflammations, including enteritis. For induction of anti-MIF auto-antibody, the vaccine incorporates a helper T epitope, a peptide fragment (TTX) from the tetanus toxin. In the present study, a new series of MIF vaccine were prepared that employed epitopes from ovalbumin (OVA), egg white lysozyme (HEL), and tetanus toxin (TET830). On the other hand, it has been confirmed that, in inflammation-induced colon cancer model, the expression of various cytokines (IL-4, IL-17a, GM-CSF), chemokines (CCL12, CCL20) and MMP3 is concord with that of MIF. Upon inoculation with the initial type MIF-DNA vaccine, carcinogenesis inhibitory effect could be confirmed with good reproducibility.
|
| Free Research Field |
生化学
|
